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ABSTRACT 
Background 
Cystic fibrosis (CF) is described more commonly in Caucasian populations in whom p.Phe508del 
is the most common mutation. There is a paucity of data of CF in black African children. The aim 
of this study was to describe and compare the presentation and outcomes of black African children 
with CF to those with p.Phe508del genotype. 
Methods 
A retrospective case-controlled study was conducted from January 2000 – March 2018 of children 
with CF attending two CF centres in South Africa. Presentation, genotype, nutrition and pulmonary 
function outcomes of black African children were compared to matched controls with the 
p.Phe508del mutation.  
Results 
Thirty-four black African children (cases) with median age of diagnosis (5.5 months, IQR 2.0-
15.0) were matched to 34 controls. Among cases, 3120+1G->A CFTR mutation was most 
commonly identified; homozygous n=22 (64.7%) and heterozygous=7(20.5%). Compared to 
controls, cases at diagnosis were more malnourished and fewer presented with neonatal bowel 
obstruction [cases n=2 (5.9%) vs. controls n=10 (29.4%); p = 0.03]. Nutrition and pulmonary 
function (FEV1 in children ≥ 6 years) outcomes and changes over time from ages 3-16 years were 
similar in both groups; median FEV1 z-score at age 6,10 and 14 years was -0.9 (±1.5), -1.8 (±2.0) 
and -1.8 (±1.9) respectively for all patients. Deaths were recorded in three cases (8.8%) and one 
control (2.9%) (p = 0.6).  
Conclusion 
Black African children with CF were more malnourished at diagnosis, and fewer presented with 
neonatal bowel obstruction. Cases and controls had comparable nutritional, pulmonary function 
and early mortality outcomes. 
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Background: Cystic fibrosis (CF) is described more commonly in Caucasian populations in whom 
p.Phe508del is the most common mutation. There is a paucity of data of CF in black African 
children. The aim of this study was to describe and compare the presentation and outcomes of 
black African children with CF to those with p.Phe508del genotype. 
Methods: A retrospective case-controlled study was conducted from January 2000 – March 2018 
of children with CF attending two CF centres in South Africa. Presentation, genotype, nutrition 
and pulmonary function outcomes of black African children were compared to matched controls 
with the p.Phe508del mutation.  
Results: Thirty-four black African children (cases) with median age of diagnosis (5.5 months, IQR 
2.0-15.0) were matched to 34 controls. Among cases, 3120+1G->A CFTR mutation was most 
commonly identified; homozygous n=22 (64.7%) and heterozygous=7(20.5%). Compared to 
controls, cases at diagnosis were more malnourished and fewer presented with neonatal bowel 
obstruction [cases n=2 (5.9%) vs. controls n=10 (29.4%); p = 0.03]. Nutrition and pulmonary 
function (FEV1 in children ≥ 6 years) outcomes and changes over time from ages 3-16 years were 
similar in both groups; median FEV1 z-score at age 6,10 and 14 years was -0.9 (±1.5), -1.8 (±2.0) 
and -1.8 (±1.9) respectively for all patients. Deaths were recorded in three cases (8.8%) and one 
control (2.9%) (p = 0.6).  
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Conclusion: Black African children with CF were more malnourished at diagnosis, and fewer 
presented with neonatal bowel obstruction. Cases and controls had comparable nutritional, 
pulmonary function and early mortality outcomes. 
Key Words 
Cystic Fibrosis, Black African children, South Africa, 
Introduction  
Cystic fibrosis (CF), is a severe life-limiting, autosomal recessive disorder identified in 1938(1). 
CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) 
gene located on chromosome 7q31.2.Currently six classes of CFTR mutations have been 
described. The first three mutations are associated with severe CF disease, this is due to complete 
absence of CFTR protein on the cell wall of epithelial cells or complete lack of function although 
present. The most  common mutation worldwide is the pPhedel508 mutation a class two mutation 
in which CFTR protein that is produced is abnormally folded and gets destroyed by the 
endoplasmic reticulum. This is a mis sense amino acid deletion.(2) The CFTR gene plays a primary 
role in chloride and bicarbonate transport with secondary effect on sodium transport(3,4). Severity 
of CF depends partly on the class of CFTR mutation, however genotype-phenotype correlates 
suggest additional genetic factors such as complex alleles, modifier genes and epigenetic factors 
significantly influence the phenotypic expression of CF(5).Cystic fibrosis is more prevalent among 
populations of European descent where the most commonly occurring mutation is p.Phe508del. 
Among non-Caucasian populations, a wide range of mutations has been reported with p.Phe508del  
mutation occurring less commonly. Cystic fibrosis is less prevalent among populations of African 
ancestry and has been sporadically reported in Kenya, South Africa(6,7)and more recently in 
Sudan and Brazil(8,9).The reported incidence of CF is 1 in 15,100 among African Americans (10). 
The true incidence of CF in sub-Saharan African is unknown (11). 
  
Due to markedly improved knowledge on cystic fibrosis disease entities over the past six decades 
the median age of survival has increased from a few months to  more than 40 years in advanced 
countries. In the past death from CF was as a result of meconium ileus and malnutrition secondary 
to pancreatic malabsorption.(12–14).  
In the 21st century death occurs mainly from respiratory failure in individuals who have not under 
gone lung transplant. The major achievements in life expectancy has been due to early institution 
of airway clearance techniques, aggressive management of airway infections and addressing 
nutritional deficits(3,15,16).  
The 3120+1G->A mutation was first reported by Macek and colleagues (17) among a small group 
of  African Americans with CF. Subsequently it was also reported among South Africans by Carles 
et al(18). The 3120+1G->A mutation, is a severe class I nonsense mutation(19) and  accounts for 
up to 14% of CF mutation in African Americans and native Africans(17). There are few and 
conflicting reports of the spectrum of CF phenotypes in African children. In a previous case series, 
 11 
people with the 3120+1G->A mutation were noted to have mild sinopulmonary symptoms and 
many presented with abdominal symptomatology, especially meconium ileus (20). By contrast, in 
a comparative study between black and white American patients with CF, meconium ileus was 
reported less commonly in the black individuals (21). Masekela et al, in a South African study, 
reported failure to thrive and protein energy malnutrition as common presentations of CF in 
individuals with 3120+1G->A mutation. All were pancreatic insufficient and acquired 
Pseudomonas aeruginosa airway infection by their second year of life (22). Pulmonary function 
outcomes were noted to be poorer in black patients with CF compared to Caucasian patients in the 
study by Hamosh et al (21). 
Cystic fibrosis has been extensively studied and characterised among  Caucasians  outside  South 
Africa (23)(24) and also among Caucasians in  South Africa(11)(25). Although awareness among 
clinicians of the existence of CF in black African children is improving, there remains a paucity 
of data on CF disease in black Africans(26).Improved knowledge of CF in African populations 
may lead to earlier diagnosis and improved outcomes. The primary aim of this study was therefore 
to compare the genotype, clinical presentation, pulmonary function and nutritional outcomes in 
black African children diagnosed with CF in SA to matched cases with p.Phe508del genotype. We 
hypothesized that genotype would be different but presentation and clinical outcomes would be 
similar. 
Methods 
Study design and setting 
A retrospective case-control study (1:1 ratio) was conducted to compare CF disease in black 
African children and children with the p. Phe508del CFTR mutation. The study was conducted in 
two paediatric CF centres in SA: Red Cross War Memorial Children’s Hospital (RWMCH), Cape 
Town, and Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in Johannesburg. The 
study was approved by Human Research Ethics committees of the University of Cape Town 
(HREC 586/2017) and University of the Witwatersrand (Protocol M171149). The requirement for 
obtaining informed consent was waived as this was a retrospective study. 
Study population. 
All black African children diagnosed with CF between 1 January 2000 and 31 March 2018, were 
included. The diagnosis of CF during the study period was confirmed on international CF 
Foundation consensus criteria: phenotypical manifestations of CF, or a family history of CF and 
either  i) two known disease-causing CFTR mutations identified or ii) two positive sweats tests 
(sweat chloride > 60 mmol/L)(27). In circumstances where sweat chloride measurements were not 
available, a diagnosis of CF was considered likely if at least two sweat conductivity tests were > 
80mmol/L in the presence of phenotypic manifestation compatible with CF. CFTR mutation panel 
testing most widely available in South Africa during the study period was Elucigene CF29v2 
(Elucigene Diagnostics, Manchester, UK). Further testing in some cases was performed 
independently where financial resources were available. 
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Matched controls homozygous with p.Phe508del CFTR mutation were identified from medical 
records at the respective CF centres using the same CF diagnosis criteria. Children heterozygous 
with p.Phe508del CFTR mutation and another mutation (excluding 3120+1G>A) were selected as 
controls if no suitable p.Phe508del homozygous control was identified. Index cases were further 
matched with controls according to the following criteria: diagnosis age (within 12 calendar 
months); gender; and year of diagnosis (within 12 calendar months). 
Clinical information at diagnosis 
Data was extracted from the medical records and existing local CF clinic databases from the two 
study sites. Demographic and country of origin details, genotype and sweat test information was 
recorded for cases and matched controls. The modes of presentation at the time of diagnosis, 
including presence of neonatal bowel obstruction, family history of CF, predominantly respiratory 
disease, predominantly gastrointestinal disease or both were recorded. The World Health 
Organisation’s (WHO) Anthro or Anthro Plus calculator (version 3.22 January 2011) was used to 
calculate weight-for-age (WAZ); height-for-age (HAZ) and weight for height (WFHZ) z-scores 
and body mass index (BMI) and BMI z-scores for children under and over 6 years of age 
respectively. All anthropometric measurements were standardly taken at the time of diagnosis and 
at subsequent follow-up visits. Participants with faecal elastase level <200ug/ml or those on 
pancreatic enzyme replacement therapy (PERT) due to steatorrhea symptoms were classified as 
pancreatic insufficient (PI). 
Outcomes 
Best calendar-year annual measurements of weight and height were documented for each study 
participant at ages 1, 3, 6, 8, 10, 12, 14 and 16 years, where available and applicable. 
Corresponding best annual pre-bronchodilator forced expiratory flow in one second (FEV1) for 
participants six years and older was also documented. Ethnic-specific Global Lung Initiative (GLI) 
equations for were applied to calculate FEV1 Z-scores for age (28).  
The age at first documented Pseudomonas aeruginosa infection was recorded as well as age of 
chronic P.aeruginosa infection as per the modified Leeds’s classification (29). Similar information 
on Staphylococcus aureus airway infection was also recorded. Mortality outcomes and causes of 
death were documented where information was available. 
Statistical analysis  
Data were tested for normality using the Shapiro-Wilks W test, and variables are presented 
throughout as median (interquartile range, IQR) or n (%) as appropriate for non-normally 
distributed data, and as mean ± standard deviation (SD) for normally distributed data. Comparisons 
between cases and controls were conducted using Mann-Whitney U or t-tests for independent 
variables for continuous variables, and chi square tests (with Yates correction where applicable) 
for categorical variables. Repeated measures analysis was conducted using ANOVA (one- way 
and between- and within-groups designs) for measures of lung function and nutritional status at 
different time periods, after testing for normality of residual distribution. A p-value of less than 
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0.05 was regarded as statistically significant. Statistica version 12 (StatSoft, USA) was used for 
analysis. 
Results 
Demographic and clinical information at diagnosis  
Thirty-four (n=21; 61.8% male) black African children (cases), matched to 34 controls, were 
recruited from the two CF centres: 15 cases and controls from RCWMCH and 19 cases and 
controls from CMJAH. Median age of diagnosis (5.5 months, IQR 2.0-15.0), and pancreatic 
insufficiency status (n=59, 86.8%) was similar in cases and controls (Table 1).  
The most common CFTR mutation identified in cases was 3120+1G>A, identified in either 
homozygous or heterozygous state in 23 (67.6%) and 6 (17.6%) cases respectively with an allele 
frequency of 55/68 (81%); in one case the two mutations identified were Gly458Val/p.Ser466X, 
and four cases (11.8%) had no mutations identified (Table 1). Among the six cases who were 
heterozygous for the 3120+1G->A mutation, there were three cases in whom the second mutation 
could not be identified, two cases with c.1585.3T>G and one with p.Arg792X as the second 
mutation. Five cases were children of parents originating from other African countries.  
Compared to controls, cases at diagnosis were significantly more malnourished, with lower BMI-
Z, WAZ, HAZ, and WFHZ scores (Table 1). Mode of presentation was similar except that cases 
were significantly less likely to present with neonatal bowel obstruction (Table 1). 
Table 1: Demographic and clinical information of cases and controls at time of CF diagnosis and 
during follow-up period. 
 Variable Cases (n=34) n (%) Controls (n=34) n (%) P-value 
Age at diagnosis months (median, 
IQR) 
5.0 (2.0 – 15.0) 6.0 (3.0 – 15.0) 1 
Male gender 21 (61.7) 17(50.0) 0.7 
Country of origin 
   
SA 29 (85.2) 34(100) 0.2 
Ghana 1(2.9) 0 
 
Malawi 2(5.9) 0 
 
Zimbabwe 1(2.9) 0 
 
Mozambique  1(2.9) 0 
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 Variable Cases (n=34) n (%) Controls (n=34) n (%) P-value 
Sweat chloride mmol/L  111.8 ± 19.0 (n=11) 108.8 ± 11.6 (n=15) 0.6 
Sweat conductivity mmol/L  103.2 ± 30.5 (n=12) 101.9 ± 38.0 (n=8) 0.7 
CFTR mutations 
   
p.Phe508del  homozygous 0 25(73.5) 
 
p.Phe508del  heterozygous 0 9(26.5) 
 
3120+1G->A homozygous 23 (67.6) 0  
3120+1G->A heterozygous 6 (17.6) 0  
Other mutations (number of 
alleles) 
Unknown (11) 
c.1585-3T>G (2) * 
p.Arg792X  
Gly458Val* 
p.Ser466X  
p.Arg1162X (2) 
Gly1173GlnfsX21* 
3272-26A>G 
p.Trp846X 
p.Arg553X  
p.Gly542X   
p.Leu88IlefsX22 (2) 
 
Pancreatic insufficient n=30 (88.2%) n=29 (85.3%) 1 
Nutritional status at diagnosis    
BMI-Z  -3.1 ± 2.2 -1.2 ± 3.2 0.009 
WAZ  -4.3 ± 2.0 -2.6 ± 1.9 0.0008 
HAZ  -3.5 ± 2.5 -2.1 ± 2.2 0.02 
WFHZ  -3.0 ± 2.1 -1.6 ±2.2 0.02 
FEV1 Z score    
Age 6 -0.9 ± 1.9 -0.9 ± 1.3 0.4 
Age 10 -2.8 ± 2.05 -1.1 ±1.3 0.08 
Age 14 -1.4 ± 1.3 -2.3  ± 2.6 0.2 
Presenting symptoms 
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 Variable Cases (n=34) n (%) Controls (n=34) n (%) P-value 
Predominantly respiratory 7(20.5) 7(21.9) 0.8 
Predominantly GIT* 9(26.47) 4(12.5) 0.6 
Combined GIT* and respiratory 16(47.1) 9(28.2) 0.1 
Neonatal bowel obstruction 2(5.9) 10(31.3) 0.03 
Family history/neonatal screening 0 2(6.3) 0.4 
Airway infections 
   
Ever PA infection  21(61.7) 24(70.6) 0.6 
Ever SA infection  26(76.5) 31(91.2) 0.2 
Age at first PA (median, IQR) 11 (5.5 – 48.5) 22.0 (12.0 – 32.0) 0.7 
Chronic PA infection 6 (17.6) 5 (14.7) 1 
Other significant infections 16 (47.1) 20(58.8) 0.5 
Comorbid conditions 6(17.6) 5(14.7) 0.4 
Learning difficulties 2(5.9) 1(2.9) 
 
ADHD 0 3 (8.8) 
Congenital heart disease 1(2.9) 0 
HIV exposed 2(5.9) 1(2.9) 
Gunshot injury to abdomen 1(2.9) 0 
Deaths 3(21.4) 1(7.1) 0.6 
  
Legend: IQR- Interquartile range, WAZ- Weight for age Z-score, HAZ Height for age Z-score, 
WFAZ-Weight for age Z-score, BMIZ-Body mass index, GIT-Gastro intestinal, ADHD-
Attention deficit Hyper activity disorder, HIV-Human immunodeficiency virus: SA- 
Staphylococcus aureus ; PA- Pseudomonas aeruginosa; Categorical data are presented as n (%) 
and continuous data as mean  SD unless otherwise indicated; * CFTR variants of unknown 
clinical significance or not reported in CFTR2 database. 
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Outcomes  
Although nutritional status was significantly poorer at diagnosis in cases compared to controls 
(Table 1), there were no significant differences between groups in the change over time (Figures 
1-3) and by three years of age there was no longer a significant difference in nutritional status 
between groups, for any outcome measures (BMI Z score, HAZ or WAZ). 
There were no differences between groups in the change of FEV1 over time (p = 0.5); and there 
were also no differences in FEV1 Z scores between groups  at specific ages (Table 1). Median age 
(15.0 months, IQR 7.0-32.0) of first documented P.aeruginosa infection and prevalence (n=11, 
16%) of chronic P.aeruginosa infection was similar in cases and controls (Table 1).   
There were three early (8.8%) deaths among cases (two with shock and respiratory failure, and 
one of unknown cause) and one (2.9%) early death in the control group, due to severe malnutrition 
and sepsis at the time of diagnosis (Table 2).  
 
 
Figure 1: Changes in mean BMI Z score over the study period between cases and controls. 
Anova current effect F (7,7) = 0.14; p = 0.99. 
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Figure 2: Change in mean HAZ throughout the study period in cases and controls. Anova 
current effect F (7, 21) = 0.79; p = 0.6. 
 
 
 
Figure 3: Change in mean WAZ from diagnosis to age 10. Anova current effect F (5, 30) = 0.65; 
p = 0.7. 
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Table 2: Details of early mortality cases 
   Patient 1  Patient 
2 
Patient 3 Patient 4  
Case/Control  Case Case  Case  Control 
Sex Male Female Male Female 
Affected Sibling  Unknown Yes Yes Yes 
Year of presentation 2005 2007 2009 2008 
Age at presentation 
(months) 
2 2 2 4 
Age at the time of death 
(months) 
5 2 3 5 
Mode of presentation *SAM/Recurrent 
Pneumonia  
SAM SAM/ 
Recurrent 
Pneumonia  
Family History 
Sweat chloride  120  Not 
done 
 Not done 122 
Genotype Negative 
 
3120+1G->A 
homozygous 
p.Phe508del  
homozygous 
Pancreatic Status  *PI PI PI PI 
Airway Infections  Staphylococcus 
aureus 
Serratia 
Not 
documen
ted 
Not documented Staphylococcus 
aureus 
Cause of Death  Sepsis  Sepsis Severe pneumonia Sepsis  
SAM -Severe acute malnutrition, PI- Pancreatic insufficient 
Discussion 
This is the largest series reported to date on CF presentation and disease course among black 
African children. Our findings highlight the features of CF disease among black African children 
for which there was previously a paucity of data. Despite some differences observed in 
presentation, clinical course and outcomes over time were similar to a matched cohort with 
p.Phe508del genotype in this non-screened population. This is important as it demonstrates 
comparable outcomes are achievable with appropriate care, regardless of genotype or race, even 
in SA which according to a World Bank report is the most unequal society in the world (30). These 
findings confirm our hypothesis that the genotypes are different among cases and controls, found 
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and mode of presentation maybe different. Despite these differences long term management 
outcomes were similar for both groups.  
At diagnosis, cases were found to be more malnourished and fewer presented with neonatal bowel 
obstruction than controls with the p.Phe508del CFTR mutation. Our finding agrees with earlier 
reports by Masekela et al (2013) in SA (22), Prapphal,(31) and Hamosh et al, in the United States 
(21), that among black ethnic populations, severe malnutrition and failure to thrive is more likely 
to be present at diagnosis with lower incidence of meconium ileus. Although socioeconomic status 
(SES) was not documented, the higher prevalence of malnutrition among cases at diagnosis in our 
study may relate to lower SES and poverty due to social and wealth inequality gaps aligned with 
racial demographics that persist in SA society  today (30). Lower SES and social deprivation are 
important determinants of poorer CF-related outcomes throughout the world(32,33). The 
occurrence of three early infant deaths among cases due to respiratory tract infection and severe 
malnutrition with complications may reflect a failure to recognise CF in the differential diagnosis 
of  children with severe malnutrition  in the SA setting in the non-Caucasian population(cases). 
Although malnutrition was more severe amongst cases at diagnosis, long term nutritional outcomes 
in our study were comparable; suggesting that severe malnutrition at diagnosis may not have long-
term impact. However, severe malnutrition in infants is an important risk factor for sepsis and may 
lead to early infant deaths as observed in our cohort.  In the absence of newborn screening, early 
diagnosis, targeted management and appropriately timed interventions are key to optimising 
clinical outcomes of CF regardless of genotype or SES.  
CF is a disease with extensive genetic heterogeneity (24). The 3120 +1G>A, a severe class I  
nonsense mutation(19), was the commonest CFTR mutation occurring among black Africans with 
CF (cases) in this series, both in homozygous and compound heterozygote states. This confirms  
previous findings that it is the most common pathogenic CFTR mutation in black African people 
with CF in the sub-Saharan Africa, with reported allele frequency ranging  between 11-46% (34) 
of tested alleles, which is lower than found in this series (81%). We speculate that this higher allele 
frequency represents a more accurate picture than previous reports which were derived from 
smaller samples (7,11,22) .The 3120+1G->A mutation is believed to be a founder mutation that 
may have existed long ago among African populations and may have spread to many different 
continents through migration (35–37).This  CFTR mutation was initially reported by Macek (35), 
among African Americans and later by Carles and colleagues in SA (18). Our current study also 
identified unknown, novel or other CFTR mutations occurring with 3120+1G->A as compound 
heterozygotes: c.1585.3T>G and p.Arg792X. This suggests the existence of several undescribed 
CFTR mutations among black African populations yet to be documented. Our series also suggests 
that genotype confirmation of CF diagnosis is possible in the majority of black Africans in sub-
Saharan Africa where, except for SA, access to CF diagnosis tests including sweat testing is not 
available. The parents of five children with CF were immigrants from neighbouring African 
countries where CF had not been previously described. This suggests that CF must occur in these 
countries, but affected children are either dying early or misdiagnosed with other conditions.  
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Our study has several important implications for future CF-related care and research in Africa. 
Firstly, understanding the disease spectrum and unique CFTR mutation profile in black Africans 
will guide the development of appropriate CF molecular diagnosis approaches including newborn 
screening strategies. Secondly, recognition that 3120+1G->A is the most prevalent CFTR mutation 
in black Africans has important treatment implications in the era of CFTR modulator therapies 
where to date no effective compound for class I nonsense CFTR mutations has been registered for 
clinical use (38,39)  This has implications for the progression of disease and long-term survival 
outcomes for patients with this mutation. Further research in the regard is warranted. 
The strength of this study lies in the number of cases recruited from the two largest paediatric CF 
centres in SA. The study is limited by the relatively young population, with no follow up to 
adulthood, and the small number of patients for whom spirometry could be documented in the long 
term.  Another limitation is that all cases and controls were those already diagnosed with typical 
CF and managed at CF centres, so this series may have excluded milder disease phenotypes or 
children who died before CF was diagnosed and is therefore not truly reflective the whole CF 
population. Environmental exposures, chronic therapies and compliance are potential confounding 
factors that could have affected outcomes but we could not evaluate these in this retrospective 
study as this information was not accurately recorded in the medical records.  Next generation 
sequencing is not widely available in routine care in SA but may have identified additional CFTR 
variants in those without genetic confirmation of CF. Further studies are warranted to document 
the genotype and phenotype trajectories over time in all ethnic groups with CF in SA. 
In conclusion, black African children with CF were more malnourished at the time of diagnosis, 
and fewer presented with neonatal bowel obstruction than patients with the p. Phe508del CFTR 
mutation. However, nutritional and pulmonary function outcomes were comparable over time. A 
high index of suspicion for CF amongst health workers is needed for black African infants 
presenting with unexplained malnutrition and other symptoms of CF disease. Continual education, 
improved CF awareness and improved access to CF diagnosis testing are needed in Africa. 
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APPENDIX 1: DATA GATHERING FORM 
 ID  Date of Data Capturing  _ _ / _ _ / __ 
 CF Clinic Site  ☐ 0 RCWMCH 
 ☐ 1 CMH 
 DOB  Hospital Number  
Q1 Date of diagnosis  _ _/ _ _ / _ _ 
Q2 Age in months at 
diagnosis  
 
Q3 Sex   ☐ 0 Male  
 ☐ 1 Female  
Q4 Country of Origin  
(Country of origin of 
parents)  
 
 
 ☐ 0 SA 
☐ 1 Zimbabwe 
☐ 2 Malawi 
☐ 3 Mozambique 
☐ 4 Botswana  
  5 Other: ________ 
Q5 Sweat (chloride) 
Conductivity 
concentration  
 ☐ -----mmol/l 
☐ -----mmol/l 
 
Q6 Genotype  ☐ 0  Delta F508 homozygous 
☐ 1 3120+1GA homozygous 
☐ 2 3120+1GA /Other: ____________________ 
☐ 3   3120+1GA/unknown 
☐ 4  Unknown/unknown 
☐  5 Other; ______________________________ 
Q7 Feacal elastase levels   
---------- ug.ml 
☐ 0 PS 
☐ 1 PI 
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Q8 
Mode of   Presentation ☐ 0 Neonatal bowel Obstruction 
☐ 1 Predominantly GIT symptoms: malnutrition 
☐ 2 Predominantly Respiratory symptoms 
☐ 3 Combined GIT and Respiratory symptoms 
☐ 4 Family history/newborn screen 
☐  5 Other 
Longitudinal Outcome Data (From diagnosis to 31st March 2017) 
Q9a Visit 0   
Date : 
Weight (Kg) Height(cm) FEV1 (L) (> 6yrs) 
Q9 b Visit 1 
Date: 
   
Q9c Visit 2 
Date: 
   
Q 9d Visit 3 
Date: 
   
Q 9e Visit 4 
Date: 
   
Q 9f Visit 5 
Date: 
   
Q 9g Visit 6 
Date: 
   
Q 9h Visit 7 
Date: 
   
Q 9i Visit 8 
Date: 
   
Q 9 j  Visit 9 
Date: 
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Q 9 k  
 
Visit 10 
Date: 
   
Q 9l Visit 11 
Date  
   
Q 9m Visit 12  
Date  
   
Q 9n Visit 13 
Date  
   
Q 9 o Visit 14 
Date 
   
Q 9p Visit 15 
Date 
   
Q9q Visit 16 
Date: 
   
Q9 r Visit 17 
Date 
   
Q9s Visit 18 
Date  
   
Q9t Visit 19 
Date 
   
Q9 u Visit 20 
Date: 
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Q10a Alive on 31 March 2017 ☐ 1Yes  
 ☐ 0 No 
Q10b If no then  
 
Date last seen: _________ 
☐ 0 Died   
☐ 1 Transfer to another facility  
☐ 2   Lost to follow up. 
Q10c If patient died, state the 
cause of death.  
 
Q11a Has patient ever had 
pseudomonas  
☐ 1 Yes 
☐ 0 No 
Q11b Date of first pseudomonas 
infection 
 
Q11c Age at first pseudomonas 
infection  
 
Q11d Chronic pseudomonas 
colonization  
☐ 1 Yes  
☐2 No 
Q11e Date at pseudomonas 
colonisation 
 
Q12f Age at first pseudomonas 
colonization 
 
Q12a Has patient ever had any 
staphylococcal infection  
☐ 1 Yes  
☐ 2 No  
Q12b Date at first 
staphylococcal infection  
 
Q12c Age at first 
staphyloccocal infections 
colonization  
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Q13a Other significant 
infections  
1 Yes  
0 No 
Q13b List significant   
Q14a Other comorbidity   1 Yes  
0 No  
Q14b List Co morbidities   
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APPENDIX 2: DEPARTMENTAL REVIEWER COMMENTS 
Review of Proposal:  
UCT Department of Paediatrics and Child Health 
Clinical science review: QUANTITATIVE  
Study Title:  
 
 
 
 
Name of reviewer (not to be shown to researcher): ANON 
 
Date submitted:       Date returned: 
Please mark the appropriate column:  
 Yes Unclear No  NA 
1. Abstract/Summary - is this complete? 
 
   
2. Background and literature review: Is the setting and the current 
practice described? Are gaps in the literature identified?  
Is the problem and purpose of the study clearly stated? Is it 
appropriately detailed depending on the research method chosen, 
and does it discuss the major concepts being studied? 
Comment: 
 
   
3. Objectives – Are objectives clearly stated and linked to the purpose?  
Comment:  
   
4. Methodology:      
     a. Design – Will the design answer the research question?  
Comment: But it depends on numbers of children in each arm. Low numbers 
may make it difficult to judge differences. Would it not be better to to have 
two control patients if possible? 
 
   
     b. Sample – Are the subjects and/or documents to be reviewed well 
described? Are there clear inclusion and exclusion criteria?  Is the sample 
representative and is there a rationale for sample size (eg power analysis)?  
Comment: See above. Sample size is not a sample – it is all available patients 
 
   
     c. Data – Is there clear description of which data will be collected? By 
whom? Is storage and security of data clear? Is each objective linked to a 
specific item or set of items of data?   
If field/community workers are collecting data, what training will they 
receive? 
Comment: The nutrition/growth parameters are inadequate. There is an 
opportunity to measure BMI/WFH (much better measures of the nutrition of 
child with CF) that should be taken. WHO has charts for young children) 
 
   
     d. Analysis – Is the statistical analysis described – (including electronic 
programme e.g. Excel, Stata, other; probability levels, confidence boundaries) 
Comment: 
 
   
5. Are the limitations stated, and appropriate to the study design, population 
and sample size? 
Comment:   
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6. Is the scope of the study feasible within the available time and resources?
Comment:
7. Ethical Considerations – Are the ethical considerations well described?
Are research subjects assured of confidentiality, anonymity and respect?
Are possible adverse effects or risks associated with the audit outcomes
described?
Comment: 
8. References – Are all references included with the same referencing
format throughout?
Comment: 
9. Appendices –  Consent and assent form (if appropriate)?  Budget? Please
note that Institutional permission must be obtained before the study
can be conducted
Comment: 
10. Timeline?
Comment:
11. Postgraduate Degree – Is the study for postgraduate degree purposes? If
so, is it appropriate for the degree level?
Comment: 
General: 
It would be useful to have some idea of how many patients are likely to be recruited. The danger is 
that there will be so few that nothing will be learnt. 
Recommendation: Approved  Conditional     Not approved 
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agree with the addition, removal or rearrangement. In the case of addition or removal of authors, 
this includes confirmation from the author being added or removed. 
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Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of 
authors after the manuscript has been accepted. While the Editor considers the request, publication 
of the manuscript will be suspended. If the manuscript has already been published in an online issue, 
any requests approved by the Editor will result in a corrigendum. 
Clinical trial results 
In line with the position of the International Committee of Medical Journal Editors, the journal will not 
consider results posted in the same clinical trials registry in which primary registration resides to be 
prior publication if the results posted are presented in the form of a brief structured (less than 500 
words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) 
is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all 
posting in registries of results of the same or closely related work. 
Randomised controlled trials 
All randomised controlled trials submitted for publication in the Journal of Cystic Fibrosis should 
include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer 
to the CONSORT statement website at http://www.consort-statement.org for more information. 
Journal of Cystic Fibrosis has adopted the proposal from the International Committee of Medical 
Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical 
trials, registration in a public trials registry. Trials must register at or before the onset of patient 
enrolment. The clinical trial registration number should be included at the end of the abstract of the 
article. For this purpose, a clinical trial is defined as any research study that prospectively assigns 
human participants or groups of humans to one or more health-related interventions to evaluate the 
effects of health outcomes. Health-related interventions include any intervention used to modify a 
biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural 
treatments, dietary interventions, and process-of-care changes). Health outcomes include any 
biomedical or health-related measures obtained in patients or participants, including pharmacokinetic 
measures and adverse events. Purely observational studies (those in which the assignment of the 
medical intervention is not at the discretion of the investigator) will not require registration. Further 
information can be found at http://www.icmje.org 
Copyright 
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see 
more information on this). An e-mail will be sent to the corresponding author confirming receipt of 
the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version 
of this agreement. 
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal 
circulation within their institutions. Permission of the Publisher is required for resale or distribution 
outside the institution and for all other derivative works, including compilations and translations. If 
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excerpts from other copyrighted works are included, the author(s) must obtain written permission 
from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for 
use by authors in these cases. 
For open access articles: Upon acceptance of an article, authors will be asked to complete an 
'Exclusive License Agreement' (more information). Permitted third party reuse of open access articles 
is determined by the author's choice of user license. 
Author rights 
As an author you (or your employer or institution) have certain rights to reuse your work. More 
information. 
Elsevier supports responsible sharing 
Find out how you can share your research published in Elsevier journals. 
Role of the funding source 
You are requested to identify who provided financial support for the conduct of the research and/or 
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in 
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to 
submit the article for publication. If the funding source(s) had no such involvement then this should 
be stated. 
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Funding body agreements and policies 
Elsevier has established a number of agreements with funding bodies which allow authors to comply 
with their funder's open access policies. Some funding bodies will reimburse the author for the Open 
Access Publication Fee. Details of existing agreements are available online. 
After acceptance, open access papers will be published under a noncommercial license. For authors 
requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication. 
Open access 
This journal offers authors a choice in publishing their research: 
Subscription 
• Articles are made available to subscribers as well as developing countries and patient groups through 
our universal access programs. 
• No open access publication fee payable by authors. 
Open access 
• Articles are freely available to both subscribers and the wider public with permitted reuse. 
• An open access publication fee is payable by authors or on their behalf, e.g. by their research funder 
or institution. 
Regardless of how you choose to publish your article, the journal will apply the same peer review 
criteria and acceptance standards. 
For open access articles, permitted third party (re)use is defined by the following Creative Commons 
user licenses: 
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) 
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective 
work (such as an anthology), as long as they credit the author(s) and provided they do not alter or 
modify the article. 
The open access publication fee for this journal is USD 3300, excluding taxes. Learn more about 
Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing. 
Green open access 
Authors can share their research in a variety of different ways and Elsevier has a number of 
green open access options available. We recommend authors see our green open access page for 
further information. Authors can also self-archive their manuscripts immediately and enable public 
access from their institution's repository after an embargo period. This is the version that has been 
accepted for publication and which typically includes author-incorporated changes suggested during 
submission, peer review and in editor-author communications. Embargo period: For subscription 
articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers 
before an article becomes freely available to the public. This is the embargo period and it begins from 
the date the article is formally published online in its final and fully citable form. Find out more. 
This journal has an embargo period of 12 months. 
Language (usage and editing services) 
Please write your text in good English (American or British usage is accepted, but not a mixture of 
these). Authors who feel their English language manuscript may require editing to eliminate possible 
grammatical or spelling errors and to conform to correct scientific English may wish to use the English 
Language Editing service available from Elsevier's WebShop. 
Informed consent and patient details 
Studies on patients or volunteers require ethics committee approval and informed consent, which 
should be documented in the paper. Appropriate consents, permissions and releases must be obtained 
where an author wishes to include case details or other personal information or images of patients 
and any other individuals in an Elsevier publication. Written consents must be retained by the author 
and copies of the consents or evidence that such consents have been obtained must be provided to 
Elsevier on request. For more information, please review the Elsevier Policy on the Use of Images or 
Personal Information of Patients or other Individuals. Unless you have written permission from the 
patient (or, where applicable, the next of kin), the personal details of any patient included in any 
part of the article and in any supplementary materials (including all illustrations and videos) must 
be removed before submission. 
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Submission 
Our online submission system guides you stepwise through the process of entering your article 
details and uploading your files. The system converts your article files to a single PDF file used in 
the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for 
final publication. All correspondence, including notification of the Editor's decision and requests for 
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revision, is sent by e-mail. 
Submit your article 
Please submit your article via http://ees.elsevier.com/jcf/. 
PREPARATION 
NEW SUBMISSIONS 
Submission to this journal proceeds totally online and you will be guided stepwise through the creation 
and uploading of your files. The system automatically converts your files to a single PDF file, which 
is used in the peer-review process. 
As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file 
to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout 
that can be used by referees to evaluate your manuscript. It should contain high enough quality 
figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at 
the initial submission. Please note that individual figure files larger than 10 MB must be uploaded 
separately. 
References 
There are no strict requirements on reference formatting at submission. References can be in any style 
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book 
title, chapter title/article title, year of publication, volume number/book chapter and the pagination 
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be 
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted 
at proof stage for the author to correct. 
Formatting requirements 
There are no strict formatting requirements but all manuscripts must contain the essential elements 
needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and 
Methods, Results, Conclusions, Artwork and Tables with Captions. 
If your article includes any Videos and/or other Supplementary material, this should be included in 
your initial submission for peer review purposes. 
Divide the article into clearly defined sections. 
Figures and tables embedded in text 
Please ensure the figures and the tables included in the single file are placed next to the relevant text 
in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should 
be placed directly below the figure or table. 
Cover letter 
Corresponding authors must provide a cover letter which includes statements answering the following 
questions: 
•Has the work been seen and approved by all co-authors? 
•How is the work clinically relevant, and how does it add to existing research? 
•Have papers closely related to the submitted manuscript been published or submitted for publication 
elsewhere? If so please provide details. 
Failure to provide a cover letter addressing each of the questions above will result in the paper being 
returned to the author. The cover letter must be uploaded as a separate submission item. 
REVISED SUBMISSIONS 
Use of word processing software 
Regardless of the file format of the original submission, at revision you must provide us with an 
editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting 
codes will be removed and replaced on processing the article. The electronic text should be prepared 
in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with 
Elsevier). See also the section on Electronic artwork. 
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' 
functions of your word processor. 
AUTHOR INFORMATION PACK 19 Nov 2017 www.elsevier.com/locate/jcf 8 
Subdivision - numbered sections 
Divide your article into clearly defined and numbered sections. Subsections should be numbered 
1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this 
numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be 
given a brief heading. Each heading should appear on its own separate line. 
Essential title page information 
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid 
abbreviations and formulae where possible. 
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) 
of each author and check that all names are accurately spelled. You can add your name between 
parentheses in your own script behind the English transliteration. Present the authors' affiliation 
addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase 
superscript letter immediately after the author's name and in front of the appropriate address. 
Provide the full postal address of each affiliation, including the country name and, if available, the 
e-mail address of each author. 
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing 
and publication, also post-publication. This responsibility includes answering any future queries about 
Methodology and Materials. Ensure that the e-mail address is given and that contact details 
are kept up to date by the corresponding author. 
• Present/permanent address. If an author has moved since the work described in the article was 
done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as 
a footnote to that author's name. The address at which the author actually did the work must be 
retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes. 
Avoid use of extraneous words such as "study" and "investigation". The title should be given in capital 
letters (not exceeding 100 letters), and a running title (not exceeding 50 letters) should also be 
provided. 
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If data from the manuscript have been presented at a meeting, list the full name, date and location 
of the meeting and reference any previous abstracts in the bibliography. 
Abstracts 
An abstract of your manuscript, summarizing the content, should be provided. A maximum of 150 
words, should be written in a structured manner (for original articles only) since this will be the 
only part of the article studied by some readers. In original articles, the Abstract should consist of 
4 paragraphs, labelled Background, Methods, Results, and Conclusions. They should briefly describe 
the problem being addressed in the study, how the study was performed and which measurements 
were carried out, the most relevant results, and what the authors conclude from the results. 
Highlights 
Highlights are mandatory for this journal. They consist of a short collection of bullet points that 
convey the core findings of the article and should be submitted in a separate editable file in the 
online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points 
(maximum 85 characters, including spaces, per bullet point). You can view example Highlights on 
our information site. 
Keywords 
A list of three to six keywords should be supplied: full instructions are provided when submitting the 
article online 
Abbreviations 
Define abbreviations that are not standard in this field in a footnote to be placed on the first page 
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first 
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article. 
Acknowledgements 
Collate acknowledgements in a separate section at the end of the article before the references and do 
not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those 
individuals who provided help during the research (e.g., providing language help, writing assistance 
or proof reading the article, etc.). 
Formatting of funding sources 
List funding sources in this standard way to facilitate compliance to funder's requirements: 
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Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; 
the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes 
of Peace [grant number aaaa]. 
It is not necessary to include detailed descriptions on the program or type of grants and awards. When 
funding is from a block grant or other resources available to a university, college, or other research 
institution, submit the name of the institute or organization that provided the funding. 
If no funding has been provided for the research, please include the following sentence: 
This research did not receive any specific grant from funding agencies in the public, commercial, or 
not-for-profit sectors. 
Units 
Follow internationally accepted rules and conventions: use the international system of units (SI). If 
other units are mentioned, please give their equivalent in SI. 
Footnotes 
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word 
processors build footnotes into the text, and this feature may be used. Should this not be the case, 
indicate the position of footnotes in the text and present the footnotes themselves separately at the 
end of the article. 
Artwork 
Electronic artwork 
General points 
• Make sure you use uniform lettering and sizing of your original artwork. 
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier. 
• Number the illustrations according to their sequence in the text. 
• Use a logical naming convention for your artwork files. 
• Indicate per figure if it is a single, 1.5 or 2-column fitting image. 
• For Word submissions only, you may still provide figures and their captions, and tables within a 
single file at the revision stage. 
• Please note that individual figure files larger than 10 MB must be provided in separate source files. 
A detailed guide on electronic artwork is available. 
You are urged to visit this site; some excerpts from the detailed information are given here. 
Formats 
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or 
convert the images to one of the following formats (note the resolution requirements for line drawings, 
halftones, and line/halftone combinations given below): 
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'. 
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi. 
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi. 
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi 
is required. 
Please do not: 
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low. 
• Supply files that are too low in resolution. 
• Submit graphics that are disproportionately large for the content. 
Color artwork 
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or 
MS Office files) and with the correct resolution. If, together with your accepted article, you submit 
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear 
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in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations 
are reproduced in color in the printed version. For color reproduction in print, you will receive 
information regarding the costs from Elsevier after receipt of your accepted article. Please 
indicate your preference for color: in print or online only. Further information on the preparation of 
electronic artwork. 
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Illustration services 
Elsevier's WebShop offers Illustration Services to authors preparing to submit a manuscript but 
concerned about the quality of the images accompanying their article. Elsevier's expert illustrators 
can produce scientific, technical and medical-style images, as well as a full range of charts, tables 
and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve 
them to a professional standard. Please visit the website to find out more. 
Figure captions 
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure 
itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but 
explain all symbols and abbreviations used. 
Tables 
Please submit tables as editable text and not as images. Tables can be placed either next to the 
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in 
accordance with their appearance in the text and place any table notes below the table body. Be 
sparing in the use of tables and ensure that the data presented in them do not duplicate results 
described elsewhere in the article. Please avoid using vertical rules and shading in table cells. 
References 
Manuscripts should use the Vancouver style for references. 
Citation in text 
Please ensure that every reference cited in the text is also present in the reference list (and vice 
versa). Any references cited in the abstract must be given in full. Unpublished results and personal 
communications are not recommended in the reference list, but may be mentioned in the text. If these 
references are included in the reference list they should follow the standard reference style of the 
journal and should include a substitution of the publication date with either 'Unpublished results' or 
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted 
for publication. 
Reference links 
Increased discoverability of research and high quality peer review are ensured by online links to 
the sources cited. In order to allow us to create links to abstracting and indexing services, such as 
Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please 
note that incorrect surnames, journal/book titles, publication year and pagination may prevent link 
creation. When copying references, please be careful as they may already contain errors. Use of the 
DOI is encouraged. 
A DOI can be used to cite and link to electronic articles where an article is in-press and full citation 
details are not yet known, but the article is available online. A DOI is guaranteed never to change, 
so you can use it as a permanent link to any electronic article. An example of a citation using DOI 
for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. 
(2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal 
of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such 
citations should be in the same style as all other references in the paper. 
Web references 
As a minimum, the full URL should be given and the date when the reference was last accessed. Any 
further information, if known (DOI, author names, dates, reference to a source publication, etc.), 
should also be given. Web references can be listed separately (e.g., after the reference list) under a 
different heading if desired, or can be included in the reference list. 
conflict of interest disclosure 
The Journal of Cystic Fibrosis has adopted the Conflict of Interest Disclosure form provided 
by the International Committee of Medical Journal Editors (ICMJI) and requests authors 
to complete it during the submission process; a copy of the form can be found here 
http://www.icmje.org/conflicts-of-interest/ 
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Data references 
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them 
in your text and including a data reference in your Reference List. Data references should include the 
following elements: author name(s), dataset title, data repository, version (where available), year, 
and global persistent identifier. Add [dataset] immediately before the reference so we can properly 
identify it as a data reference. The [dataset] identifier will not appear in your published article. 
References in a special issue 
Please ensure that the words 'this issue' are added to any references in the list (and any citations in 
the text) to other articles in the same Special Issue. 
Reference management software 
Most Elsevier journals have their reference template available in many of the most popular reference 
management software products. These include all products that support Citation Style Language 
styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from 
these products, authors only need to select the appropriate journal template when preparing their 
article, after which citations and bibliographies will be automatically formatted in the journal's style. 
If no template is yet available for this journal, please follow the format of the sample references and 
citations as shown in this Guide. 
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following 
link: 
http://open.mendeley.com/use-citation-style/journal-of-cystic-fibrosis 
 41 
When preparing your manuscript, you will then be able to select this style using the Mendeley plugins 
for Microsoft Word or LibreOffice. 
Reference formatting 
There are no strict requirements on reference formatting at submission. References can be in any style 
or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book 
title, chapter title/article title, year of publication, volume number/book chapter and the pagination 
must be present. Use of DOI is highly encouraged. The reference style used by the journal will be 
applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted 
at proof stage for the author to correct. If you do wish to format the references yourself they should 
be arranged according to the following examples: 
Reference style 
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors 
can be referred to, but the reference number(s) must always be given. 
List: Number the references (numbers in square brackets) in the list in the order in which they appear 
in the text. 
Examples: 
Reference to a journal publication: 
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun 
2010;163:51–9. 
Reference to a book: 
[2] Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000. 
Reference to a chapter in an edited book: 
[3] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith 
RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304. 
Reference to a website: 
[4] Cancer Research UK. Cancer statistics reports for the UK, http://www.cancerresearchuk.org/ 
aboutcancer/statistics/cancerstatsreport/; 2003 [accessed 13 March 2003]. 
Reference to a dataset: 
[dataset] [5] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt 
disease and surrounding forest compositions, Mendeley Data, v1; 2015. https://doi.org/10.17632/ 
xwj98nb39r.1. 
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 
should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for 
Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples 
of Formatted References). 
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Journal Abbreviations Source 
Journal names should be abbreviated according to this list of title word abbreviations: 
http://www.issn.org/2-22661-LTWA-online.php. 
Video 
Elsevier accepts video material and animation sequences to support and enhance your scientific 
research. Authors who have video or animation files that they wish to submit with their article are 
strongly encouraged to include links to these within the body of the article. This can be done in the 
same way as a figure or table by referring to the video or animation content and noting in the body 
text where it should be placed. All submitted files should be properly labeled so that they directly 
relate to the video file's content. In order to ensure that your video or animation material is directly 
usable, please provide the files in one of our recommended file formats with a preferred maximum 
size of 150 MB in total. Any single file should not exceed 50 MB. Video and animation files supplied 
will be published online in the electronic version of your article in Elsevier Web products, including 
ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or 
animation or make a separate image. These will be used instead of standard icons and will personalize 
the link to your video data. For more detailed instructions please visit our video instruction pages. 
Note: since video and animation cannot be embedded in the print version of the journal, please 
provide text for both the electronic and the print version for the portions of the article that refer to 
this content. 
Supplementary material 
Supplementary material such as applications, images and sound clips, can be published with your 
article to enhance it. Submitted supplementary items are published exactly as they are received (Excel 
or PowerPoint files will appear as such online). Please submit your material together with the article 
and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to 
supplementary material during any stage of the process, please make sure to provide an updated file. 
Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option 
in Microsoft Office files as these will appear in the published version. 
RESEARCH DATA 
This journal encourages and enables you to share data that supports your research publication 
where appropriate, and enables you to interlink the data with your published articles. Research data 
refers to the results of observations or experimentation that validate research findings. To facilitate 
reproducibility and data reuse, this journal also encourages you to share your software, code, models, 
algorithms, protocols, methods and other useful materials related to the project. 
Below are a number of ways in which you can associate data with your article or make a statement 
about the availability of your data when submitting your manuscript. If you are sharing data in one of 
these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to 
the "References" section for more information about data citation. For more information on depositing, 
sharing and using research data and other relevant research materials, visit the research data page. 
Data linking 
If you have made your research data available in a data repository, you can link your article directly to 
the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with 
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relevant repositories, giving readers access to underlying data that gives them a better understanding 
of the research described. 
There are different ways to link your datasets to your article. When available, you can directly link 
your dataset to your article by providing the relevant information in the submission system. For more 
information, visit the database linking page. 
For supported data repositories a repository banner will automatically appear next to your published 
article on ScienceDirect. 
In addition, you can link to relevant data or entities through identifiers within the text of your 
manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; 
PDB: 1XFN). 
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Mendeley Data 
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and 
processed data, video, code, software, algorithms, protocols, and methods) associated with your 
manuscript in a free-to-use, open access repository. Before submitting your article, you can deposit 
the relevant datasets to Mendeley Data. Please include the DOI of the deposited dataset(s) in your 
main manuscript file. The datasets will be listed and directly accessible to readers next to your 
published article online. 
For more information, visit the Mendeley Data for journals page. 
Data statement 
To foster transparency, we encourage you to state the availability of your data in your submission. 
This may be a requirement of your funding body or institution. If your data is unavailable to access 
or unsuitable to post, you will have the opportunity to indicate why during the submission process, 
for example by stating that the research data is confidential. The statement will appear with your 
published article on ScienceDirect. For more information, visit the Data Statement page. 
Additional Information 
Authors should use the 'Track Changes' option when revising their manuscripts, so that any changes 
made to the original submission are easily visible to the Editors. Those revised manuscripts upon 
which the changes are not clear may be returned to the author. 
Specific comments made in the Author Comments in response to referees' comments must be 
organised clearly. For example, use the same numbering system as the referee, or use 2 columns of 
which one states the comment and the other the response. 
AFTER ACCEPTANCE 
Online proof correction 
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing 
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APPENDIX 6: REVIEWER COMMENTS 
REVIEWER COMMENTS  
Reviewer #1: Cystic fibrosis is a life-limiting, multisystemic, autosomal recessive disorder. Its 
incidence varies and is higher in Caucasian communities of Northern European ancestry. More 
than 2000 variants of the Cystic Fibrosis Transmembrane Regulator (CFTR) gene have been 
reported so far, and the variant F508del remains the most common. Cystic fibrosis (CF) in black 
African population is less frequently encountered and has been poorly described. In this paper, 
the authors compared a cohort of CF black African children with matched controls carrying the 
variant F508del to determine differences in clinical presentation and outcomes in black African 
children diagnosed with CF. 
 
Below are some suggestions for the authors to consider. 
 
Major comments: 
1. The objectives of the study were not clearly stated in a dedicated section (both in the abstract 
and core text). Although the aim of the study is shortly mentioned in the introduction, the authors 
could consider including a specific section describing the primary and secondary objectives in 
more detail. What aspects of the clinical presentation are they exactly looking for? Which 
outcomes will be compared between the two groups (e.g. lung function decline, BMI, 
exacerbation rates, mortality)? Did the authors postulate hypotheses about the differences they 
were expecting between the cases and the controls?  
Response:  Thank you for these suggestions. We have revised the last paragraph of 
Introduction to reflect the aims and hypothesis of this study as suggested: “The primary 
aim of this study was therefore to describe and compare the genotype, clinical presentation, 
pulmonary function and nutritional outcomes in black African children diagnosed with CF 
in SA to matched cases of children in South Africa with. p.Phe508del genotype.  We 
hypothesized that genotype is different but presentation and clinical outcomes would be 
similar”. 
 
2. The authors mentioned that children heterozygous with p.Phe508del mutation and another 
mutation were selected as controls if no suitable p.Phe508del homozygous control was 
identified. In these cases, was the second mutation a mutation with residual function or not? If 
so, can the authors comment on the potential impact on the results by choosing these controls? 
Response:  We did not include the details of the “Other” mutations in p.Phe508del 
heterozygotes as we believed the similar proportion of pancreatic sufficient cases in each 
group (88.2% cases, 85.3% controls) demonstrates sufficient evidence of equal prevalence 
of mutations with residual function in each group. For completeness we now have listed all 
the other mutations in control group too, table 1. 
 
3. Comorbid conditions listed in Table 1 include health issues that are not necessarily associated 
with CF (ADHD, HIV, etc.). It might have been interesting to include other comorbidities related 
to CF such as rhinosinusitis, diabetes or distal intestinal obstruction syndrome (DIOS) to 
determine if their prevalence seems to be different between the two groups. 
Response: We included these non-CF related comorbidities to highlight these 
socioeconomic and other factors in our setting that could potentially have influenced CF-
related outcomes. There were no cases of diabetes or DIOS in this cohort. Rhinosinusitis is 
a very common symptom in all children in SA and therefore not commonly recorded in the 
CF medical records.  
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4. FEV1 is typically expressed as a percent predicted by comparing the person's value in litres to 
a healthy reference population taking into consideration age, height, race, and sex. A less 
common method is to report Z-scores (number of standard deviations from the mean value). Can 
the authors comment about why they have not presented the FEV1 data as % predicted and chose 
to use Z-scores instead? 
Response: We recognise that FEV1 has been conventionally reported as percent predicted. 
Global Lung Initiative (GLI) ethnic-specific reference equations and expression of LF as z-
scores , however, are preferred for two reasons: 1) there was no normative spirometry data 
for black African children prior to GLI. Historical reference equations for “African-
Americans” are unsuitable for African children and result in under estimation of lung 
function; 2) Expression of lung function in standard deviations is considered by GLI more 
appropriate as it removes any age-related bias and is a better representation of normative 
LF distribution. We refer the reviewer to recent commentary on this matter which 
supports our view that z-scores are preferable to percent predicted: 
https://breathe.ersjournals.com/content/9/6/462.  
Not sure whether to present % predicted values- my sense is will be same? 
5. Significant differences in nutritional status based on height, weight and BMI Z-scores were 
reported between the two groups. Although statistically significant, do the authors consider these 
differences clinically significant? It would be useful to include some discussion in the 
manuscript about the clinical importance of this difference, if there is one. 
Response: We do consider these differences as clinically significant as malnutrition in 
infancy predisposes to severe infection and sepsis. Although numbers are too small for 
meaningful analysis, it is important to note that all CF-related deaths reported in this 
cohort were sepsis-related and occurred at or soon after the time of CF diagnosis.  An 
important contributing factor was likely to have been severe malnutrition. We have added 
a comment about this in the second paragraph in Discussion: “However, severe 
malnutrition in infants is an important risk factor for sepsis and may lead to early infant 
deaths as observed in our cohort.  In the absence of newborn screening, early diagnosis, 
targeted management and appropriately timed interventions are key to optimising clinical 
outcomes of CF, regardless of genotype or SES.” 
 
6. The authors mentioned some limitations of their study and commented about the potential 
impact of low socioeconomic status on their results. Did they identify other possible confounding 
factors (e.g. environmental exposures, chronic lung therapies, compliance, etc.)? Could they 
comment about selection bias, confusion bias and missing data? 
Response:  We thank the reviewer for highlighting these additional limitations. Although 
environmental exposures, chronic therapies and compliance are potential confounding 
factors, we could not evaluate these in this retrospective study because this information was 
not accurately recorded in the medical records.  We believe the cases accurately represent 
all black African children diagnosed with CF at the two centres over the study period as 
both CF clinics keep comprehensive historical medical records. However, this data will 
have excluded any children who died before CF was diagnosed or considered as a cause of 
illness or malnutrition. A higher case: control ratio (e.g. 1:2) would have been preferable 
and eliminated any selection bias in controls but we were limited by the small number of 
matched controls in our setting. We have highlighted these additional limitations in the 
Discussion. 
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7. Some ideas and discussion points are uneasy to grasp and fully understand as the phrasing is 
sometimes difficult to follow or words seem to be missing. For example: "Firstly, understanding 
the disease spectrum and unique CFTR mutation profile in black Africans will guide the 
development (of?) future diagnosis strategies including newborn screening approaches." 
Response: We have rephrased this statement as follows: “Firstly, understanding the disease 
spectrum and unique CFTR mutation profile in black Africans will guide the development 
of appropriate CF molecular diagnosis approaches including newborn screening 
strategies.” 
 
Minor comments: 
1. The authors may consider to uniformize the format better. For example, they should probably 
use the same nomenclature for the p.Phe508del mutation; it varies in the text and both 
p.Phe508del and phe508del are used intermittently. Titles, punctuation and spaces between 
words/sentences should also be uniformized.  
Response:  Thank you for pointing out these inconsistencies. We have addressed and 
corrected this in the manuscript. Where possible, we have used the protein sequence 
nomenclature or legacy name (where protein sequence not reported)- which is more 
familiar to most readers. 
2. It would have been interesting to include a table summarizing the FEV1 Z-scores instead of 
only describing a portion of them in the text. 
Brenda- could we maybe add this? Not sure if permissible to add another table? 
3. Figure 1-3: When printed in black and white, the distinction between the lines is impossible to 
perceive in the figures.  
Can we replace the colours with other data point markers along the lines? 
4. The section title "conclusion" should be presented as the others, in bold and numbered.  
Response: We have reformatted all headings and sub-headings without numbering now. 
 
Reviewer #2: This is an interesting and important report proving that African cases with CF may 
have the same quality of life and life expectancy when properly treated and diagnosed early. The 
authors also disputed previous reports on the "worse" course of CF in Africans, based on small 
and/or clinically heterogeneous cohorts.  
Generally the paper is well written, but several additional issues need to be addressed: 
1) the paper did not specify genetic testing and which variants were previously tested?  
Response:  genetic testing available in South Africa for routine diagnosistic use over the 
study period varied from single variant PCR (p.Phe508del) as first step , to the Elucigene 
CF29v2 kit   which includes 29 common variants including c.2988+1G>A. In a few cases 
clinicians were able to do next generation sequencing through private funding or pro-bono 
offers by private laboratories. We have now included a sentence in Methods describing the 
genetic testing. Where possible, we have used the protein sequence nomenclature or legacy 
name (where protein sequence not reported)- which is more familiar to most readers. 
 
2) proper variant nomenclature should be used and indicated according to CFTR1 database 
Response: Thank you for highlighting this oversight. We have revised all variant 
nomenclature according to current CFTR database nomenclature where this was provided.  
3) additional CFTR variants should be discussed in terms of their clinical annotation in 
CFTR2.org, is there any differences, naturally where appicable? 
Response: we have now listed all the other variants in table 1 and highlighted with a * those 
not reported (1)   or variants with unknown significance (2). 
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4) the authors did not discuss whether consanguinity was present in examined 3120+1 G>A 
homozygotes.  
Response: there was no consanguinity in this cohort. Consanguinity is extremely rare in the 
local population. 
 
5) sweat chloride concentrations / it is not clear how these were established (conductance versus 
pilocarpine iontophoresis)? 
Response: The two CF centres used different sweat collection and analysis techniques. Both 
techniques however stimulate sweat glands with pilocarpine iontophoresis.  The centre in 
Cape Town performs Gibson and Cooke collection method with sweat  chloride analysis 
while the centre in Johannesburg collect and analyse sweat using the Macroduct 
(Sweatcheck) Conductance analyser. This centre does not have facilities to measure sweat 
chloride in the collected sweat sample and therefore conductance (> 80 mmol/L) was 
considered diagnostic for CF as per recommended guidelines. 
6) how P. aeruginosa bronchial colonisation was established?  
Response:  respiratory samples are routinely collected at clinic visits and submitted for CF 
pathogen cultures. We adopted and cited (ref no 22) the Modified Leeds criteria to define 
colonisation.  
7) how do the authors explain family history of previous CF-related deaths in given families (e.g. 
due to lower socioeconomic status, neglect)? 
Response: This particular family did not return for genetic counselling after the death of 
the first sibling and were untraceable until the second child presented. Poor SES and 
limited insight into genetic diseases as well as untraceable contact numbers were likely 
factors. 
 
 
